Company Overview and News

2
10 Dividend Stocks You Can Set and Forget

2018-04-16 investorplace
Tired of keeping a close eye on financial news and popping in and out of positions in an effort to get the most out of an increasingly volatile market?

 
10 High-Dividend Stocks to Buy When the Market Is Blue

2018-04-13 investorplace
President Donald Trump ran on a ticket of making America great again. While the consensus on that point is very much split, what’s not deniable is the markets’ response. Trump’s pro-business agenda was credited with sparking an impressive rally. With enthusiasm overshooting rationality, however, high-dividend stocks are suddenly looking very attractive to investors.

 
GlaxoSmithKline Is A Good Buy - Cramer's Lightning Round (4/6/18)

2018-04-09 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, April 6.

 
If I Had To Build An Income Portfolio Today - Update 28

2018-04-09 seekingalpha
This article is Update 28 to my original article entitled "If I Had to Build An Income Portfolio Today."

 
This Dividend Stock Gave Up Just 30% Of The S&P 500's Value Collapse

2018-04-03 seekingalpha
Iron Mountain stands like a rock against fear and dread and offers 25% higher income than its normal yield.

 
 
Top 50 S&P 500 By Yield, Gains And Upside For March

2018-03-16 seekingalpha
"The S&P 500 is widely regarded as the best single gauge of large-cap U.S. equities. The index includes 500 leading companies and captures approximately 80% of available market capitalization." - us.spindices.com.

1
10 High-Dividend Stocks to Buy When the Market Is Blue | InvestorPlace

2018-03-07 investorplace
President Donald Trump ran on a ticket of making America great again. While the consensus on that point is very much split, what’s not deniable is the markets’ response. Trump’s pro-business agenda was credited for sparking an impressive rally. With enthusiasm overshooting rationality, however, high-dividend stocks are suddenly looking very attractive to investors.

 
Spring Sale At Iron Mountain: Closing The Valuation Gap

2018-03-05 seekingalpha
Two weeks ago, Iron Mountain announced Q4-17 and full-year results. The market sentiment was negative and shares fell 10%.

1
If I Had To Build An Income Portfolio Today - Update 27

2018-03-05 seekingalpha
This article is Update 27 to my original article entitled "If I Had to Build An Income Portfolio Today."

 
Iron Mountain Incorporated (Delaware) REIT Has Deep Debt

2018-02-21 investorplace
Iron Mountain Incorporated (Delaware) REIT (NYSE:IRM) missed its quarterly estimates. Since becoming a real estate investment trust (REIT) four years ago, the record storage company has expanded its digital storage capacity and grown its international footprint.

 
Philip Morris Gets Morgan Stanley In Its Corner

2018-02-17 seekingalpha
By extension, this includes Altria Group, which is PM's chosen domestic distributor of the IQOS heated tobacco system.

 
IRM / Iron Mountain Incorporated. (REIT) 10-K (Annual Report)

2018-02-17 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
IRM / Iron Mountain Incorporated. (REIT) 8-K (Current Report)

2018-02-17 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC  20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): February 16, 2018   IRON MOUNTAIN INCORPORATED (Exact Name of Registrant as Specified in Its Charter)   Delaware (State or Other Jurisdiction of Incorporation)   1-13045   23-2588479 (Commission File Number)   (IRS Employer Identification No.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 46284V101